If you have been reading about Dihexa and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
In 1965, Alan Stillman opened the first TGI Fridays restaurant in Manhattan. He lived on 63rd Street between First and York Avenues, in a neighborhood with many airline stewardesses, fashion models, secretaries, and other young, single people on the East Side of Manhattan near the Queensboro Bridge. He hoped that opening a bar would help him meet women. Stillman's choices for socializing were non-public cocktail parties or guys' beer-drinking hangout bars that women usually would not visit; he recalled that "there was no public place for people between, say, twenty-three to thirty-seven years old, to meet." He sought to recreate the comfortable cocktail party atmosphere in public despite having no experience in the restaurant business. With US$5,000 of his own money and $5,000 borrowed from his mother, Stillman purchased a bar he often visited, The Good Tavern at the corner of 63rd Street and First Avenue, and renamed it TGI Fridays after the expression "Thank God it's Friday!" from his years at Bucknell University. The restaurant opened on March 15, 1965, serving standard American cuisine, bar food, and alcoholic beverages, and emphasized food quality and preparation. The exterior featured a red-and-white striped awning and blue paint; the Gay Nineties interior included Tiffany-style lamps, wooden floors, Bentwood chairs, and striped tablecloths; and the bar area added brass rails and stained glass.
IGF-1, IGF receptors (IGF-1R) and IGF binding proteins (IGFBP). The therapeutic applications of IGF-1 are limited due to its poor central uptake and potential side-effects. IGF-1 that is not bound to its binding protein bears a very short half-life and is cleaved by enzymes to form the tripeptide glycine-proline-glutamate (GPE). However, the enzymatic instability of GPE, with a plasma half-life of less than 4 minutes, is further cleaved to produce the final product, cyclic-Glycine-Proline (cGP).
Because the risks of warfarin – which is used to treat blood clots – in a relatively young and otherwise healthy population are low, while the risk of adverse physical and psychological outcomes for untreated transgender patients is high, prothrombotic mutations (such as factor V Leiden, antithrombin III, and protein C or S deficiency) are not absolute contraindications for hormonal therapy. A 2018 cohort study of 2842 transfeminine individuals in the United States treated with a mean follow-up of 4.0 years observed an increased risk of VTE, stroke, and heart attack relative to a cisgender reference population. The estrogens used included oral estradiol (1 to 10 mg/day) and other estrogen formulations. Other medications such as antiandrogens like spironolactone were also used. A 2025 Dutch retrospective cohort study reported lower or similar risks for arterial cardiovascular events, but an elevated risk of venous thromboembolism. In 2,714 transgender women receiving gender-affirming hormone therapy, with 23,907 person-years of follow-up during the observation period, the study found that after adjustment for socioeconomic status, transgender women had a lower risk of myocardial infarction, a similar risk of ischaemic cerebrovascular accident, and a higher risk of venous thromboembolism compared with general-population men. A 2019 systematic review and meta-analysis found an incidence rate of VTE of 2.3 per 1000 person-years with feminizing hormone therapy in transgender women.
Sources: en.wikipedia.org
On 3 May, the South China Morning Post reported that two US Air Force C-17 planes were spotted landing at Beijing Capital International Airport. These planes are routinely used to transport the president or vice-president's motorcade and support gear—including the "heavily armed presidential motorcade" known as "The Beast"—before overseas trips. The incident therefore ignited speculation that it was in preparation for Trump's planned visit to China. On 6 May, two black SUVs with tinted windows and US government plates were spotted in a Beijing highway, thought to be in preparation of Trump's visit. On 11 May, Chinese foreign ministry confirmed that Trump will pay a state visit to China from 12 to 15 May. The US principal deputy press secretary Anna Kelly stated that Trump will visit the Temple of Heaven and a state banquet during this visit. On 11 May, Trump announced he would have a discussion with Xi Jinping on the matter of arms sales to Taiwan, breaking with the Six Assurances. Trump posted on Truth Social and stated that he was looking forward to trip to China, which he called "an amazing country". On 13 May, the Chinese Embassy to the US posted on X stating "four red lines in China–US relations must not be challenged", namely "the Taiwan Question", "Democracy and Human Rights", "Paths and Political Systems" and "China's Development Right".
== T == T cell - T-cell antigen receptors - tachykinin - tachykinin receptor - talin protein - tandem repeat sequence - taste bud - TATA box - tax gene product - taxonomy - telophase - tertiary structure - tetrodotoxin - thermochemistry - thermometer - thiamin - thioredoxin - threonine - thrombin - thrombin receptor - thrombomodulin - thromboxane receptor - thylakoid - thyroid hormone receptor - thyrotropin - thyrotropin receptor - thyrotropin-releasing hormone receptor - thyroxine - timeline of biology and organic chemistry - titration - tobacco mosaic virus - topoisomerase - toxin - trans-activator - transcription factor - transcription factor AP-1 - transducin - transformation - transforming growth factor - transforming growth factor alpha - transforming growth factor beta - transforming growth factor beta receptor - transient receptor potential - translation (biology) - transmembrane ATPase - transmembrane helix - transmembrane protein - transmembrane receptor - transport protein - transport vesicle - triiodothyronine - trinucleotide repeat - triose - tropomyosin - troponin - tryptophan - tubulin - tumor necrosis factors - tumor necrosis factor receptor - tyrosine - tyrosine 3-monooxygenase
== Veterinary use == Sufentanil is used both as an analgesic and as part of an anaesthetic protocol. In cats the half-life of sufentanil is longer than that of fentanyl and alfentanil. In dogs sufentanil produces a better anaesthetic recovery with similar analgesic and respiratory depression than fentanyl. One report suggest that for post-operative pain bupivacaine and sufentanil provides greater analgesia than fentanyl and bupivacaine in dogs. There is little information on the use of sufentanil in large animals. Due to the greater risk of cardiovascular and respiratory depression sufentanil is rarely used in practice.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.